Has AbbVie Stock Become Too Expensive to Buy?
The drugmaker’s stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.
AbbVie (ABBV) stock has been a study in momentum, climbing over 25% in the last three months and trading near its 52-week high. For a biotechnology giant with a market capitalization of about $470.2 billion, this is a powerful run. It pulls investors in with the promise of more, while whispering a warning about chasing performance. The question for any would-be buyer is whether this is momentum with fuel, or momentum that is already fully priced.
The engine is firing on more than one cylinder.
This is not a speculative run. AbbVie’s stock performance is bolted to a genuine business engine that is outperforming the broader market. The company’s operating margin over the last twelve months is a formidable 34%, far outpacing the S&P 500 median of 18.4%. Its ability to convert sales into cash is similarly strong, with an operating cash flow margin of 30% against the market’s 22%. Revenue growth is also beating the market, coming in at 10.4% against the S&P 500 median of 8.4%.
This financial power comes from a thriving product portfolio. The company’s immunology and neuroscience portfolios are driving the growth, with key drugs SKYRIZI and RINVOQ each delivering sales growth of roughly 24% in the latest quarter. The performance was strong enough for management to state, “Based on this momentum, we are raising our full year revenue guidance by 300 million.”
A premium ticket buys a seat at a premium show.
The market sees this quality, and it charges accordingly. A buyer today pays a price-to-earnings multiple of 74.5, a steep premium to the S&P 500 median of 23.5. The price-to-sales multiple tells a similar story, at 7.3 versus the market’s 3.3. The price of admission is high because the performance has been exceptional. For investors who prefer to own the entire theme, a broad healthcare ETF like XLV offers exposure to the sector without concentrating on a single name.
The real catch is that at 74.5 times earnings, the stock leaves very little margin for error. Any business stumble won’t just slow growth—it risks a sharp multiple compression that could quickly unwind recent gains. Competitors are not standing still. On the latest earnings call, analyst questions zeroed in on Rinvoq’s long-term runway, pressing management on peak sales expectations for vitiligo and alopecia in an ‘increasingly crowded development landscape.’ While management expresses confidence, the long-term story depends on its pipeline delivering the next wave of treatments to fend off rivals. Any execution stumble on a key new drug could challenge the growth narrative that justifies the stock’s premium valuation.
The Crohn’s disease franchise is the immediate test.
AbbVie’s strategy is clear: build new sources of growth to support performance well into the future, evidenced by its planned acquisition of Apogee Therapeutics. But the most immediate and telling test of its momentum is closer at hand. The company is awaiting a U.S. regulatory decision for a subcutaneous version of SKYRIZI for Crohn’s disease, which management expects “later this fall.” This is a critical expansion for one of its primary growth drivers. A smooth approval and successful launch would be a clear signal that the engine is still pulling with force.
If momentum backed by real numbers is your hunting ground, our Guidance Momentum screen tracks every S&P 500 name where a rising forecast is meeting real price strength.
Winners Take Over Portfolios Quietly
Quality stocks in uptrends are exactly the positions that quietly take over portfolios. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.